Vascular-targeting agent

A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.<ref>,

 Vascular Targeting Agents as Cancer Therapeutics, 
 , 
 2004,
 
 
 
 
 
 
 Full text,</ref>

VTAs can be small-molecule or ligand-based.

Small-molecule VTAs include:

• microtubule destabilizing drugs such as combretastatin A-4 disodium phosphate (CA4P), ZD6126, AVE8062, Oxi 4503
• vadimezan (ASA404)

Clinical trials

Phase II : ZD6126, CA4P, plinabulin (NPI-2358)<ref>

NPI-2358(link). {{{website}}}. clinicaltrials.gov.

</ref><ref>Monica M. Mita,

 Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas, 
 Clin Cancer Res, 
 2010,
 Vol. 16(Issue: 23),
 pp. 5892–5899,
 DOI: 10.1158/1078-0432.CCR-10-1096,
 PMID: 21138873,</ref><ref name=Staff2009>Staff, 
 Clinical Trials Update, 
 Genetic Engineering & Biotechnology News, 
 2009,
 Vol. 29(Issue: 8),
 pp. 58,</ref>

Phase III : DMXAA (ASA404).

References

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

This article is a stub. You can help WikiMD by registering to expand it. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health & wellness encyclopedia.